Calidi Biotherapeutics, Inc. Operating Expenses
Calidi Biotherapeutics, Inc. (CLDI) reported Operating Expenses of $4.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $4.15M, a 26.73% decline year-over-year.
- Calidi Biotherapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $4.19M, a 17.29% decline year-over-year.
- Calidi Biotherapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $4.47M, a 10.93% increase year-over-year.
- Calidi Biotherapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $5.05M, a 3.41% decline year-over-year.
- Calidi Biotherapeutics, Inc. operating expenses for fiscal 2025 was $20.24M, a 7.05% decline from fiscal 2024.
- Calidi Biotherapeutics, Inc. operating expenses for fiscal 2024 was $21.78M, a 24.89% decline from fiscal 2023.
- Calidi Biotherapeutics, Inc. operating expenses for fiscal 2023 was $28.99M, a 25.11% increase from fiscal 2022.
- Calidi Biotherapeutics, Inc. operating expenses for fiscal 2022 was $23.17M.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 6 month as first filed | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.15M 10-Q · filed 2026-08-13 | $8.34M 10-Q · filed 2026-08-13 | $12.80M derived: sum of 3 quarters · filed 2026-08-13 | $17.85M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $4.19M 10-Q · filed 2026-05-14 | $8.65M derived: sum of 2 quarters · filed 2026-05-14 | $13.70M derived: sum of 3 quarters · filed 2026-05-14 | $19.36M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $9.51M derived: sum of 2 quarters · filed 2026-03-27 | $15.18M derived: sum of 3 quarters · filed 2026-08-13 | $20.24M 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | $5.05M 10-Q · filed 2025-11-13 | $10.71M derived: sum of 2 quarters · filed 2026-08-13 | $15.77M 10-Q · filed 2025-11-13 | $19.80M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $5.66M 10-Q · filed 2026-08-13 | $10.73M 10-Q · filed 2026-08-13 | $14.75M derived: sum of 3 quarters · filed 2026-08-13 | $19.98M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | $5.06M 10-Q · filed 2026-05-14 | $9.09M derived: sum of 2 quarters · filed 2026-05-14 | $14.31M derived: sum of 3 quarters · filed 2026-05-14 | $20.09M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $4.03M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $9.25M derived: sum of 2 quarters · filed 2026-03-27 | $15.02M derived: sum of 3 quarters · filed 2026-03-27 | $21.78M 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | $5.23M 10-Q · filed 2025-11-13 | $11.00M derived: sum of 2 quarters · filed 2025-11-13 | $17.75M 10-Q · filed 2025-11-13 | $27.57M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | $5.77M 10-Q · filed 2025-08-08 | $12.52M 10-Q · filed 2025-08-08 | $22.34M derived: sum of 3 quarters · filed 2025-08-08 | $29.57M derived: sum of 4 quarters · filed 2025-08-08 | ||||
| 2024-03-31 | $6.75M 10-Q · filed 2025-05-14 | $16.57M derived: sum of 2 quarters · filed 2025-05-14 | $23.79M derived: sum of 3 quarters · filed 2025-05-14 | $30.33M derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | $9.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $17.04M derived: sum of 2 quarters · filed 2025-03-31 | $23.58M derived: sum of 3 quarters · filed 2025-03-31 | $28.99M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $7.22M 10-Q · filed 2024-11-12 | $13.76M derived: sum of 2 quarters · filed 2024-11-12 | $19.17M 10-Q · filed 2024-11-12 | $23.86M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | $6.54M 10-Q · filed 2024-08-13 | $1.50M 10-Q · filed 2023-08-21 | $11.95M 10-Q · filed 2024-08-13 | $3.52M 10-Q · filed 2023-08-21 | $16.64M derived: sum of 3 quarters · filed 2024-08-13 | $23.63M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $5.41M 10-Q · filed 2024-05-14 | $2.03M 10-Q · filed 2023-05-15 | $10.10M derived: sum of 2 quarters · filed 2024-05-14 | $17.09M derived: sum of 3 quarters · filed 2024-05-14 | $17.45M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $4.69M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $11.67M derived: sum of 2 quarters · filed 2024-03-15 | $12.04M derived: sum of 3 quarters · filed 2024-03-15 | $23.17M 10-K · filed 2024-03-15 | $4.67M 10-K · filed 2023-03-31 | |||
| 2022-09-30 | $6.99M 10-Q · filed 2023-11-14 | $1.06M 10-Q · filed 2022-11-14 | $7.35M derived: sum of 2 quarters · filed 2023-11-14 | $18.48M 10-Q · filed 2023-11-14 | $1.95M 10-Q · filed 2022-11-14 | $8.48M derived: sum of 4 quarters · filed 2023-11-14 | ||
| 2022-06-30 | $361.62K 10-Q · filed 2023-08-21 | $890.48K 10-Q · filed 2023-08-21 | $1.49M derived: sum of 3 quarters · filed 2023-08-21 | $2.59M derived: sum of 4 quarters · filed 2023-08-21 | ||||
| 2022-03-31 | $528.86K 10-Q · filed 2023-05-15 | $1.13M derived: sum of 2 quarters · filed 2023-05-15 | $2.23M derived: sum of 3 quarters · filed 2023-05-15 | $2.31M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $603.52K derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | $1.70M derived: sum of 2 quarters · filed 2023-03-31 | $1.78M 10-K · filed 2023-03-31 | |||||
| 2021-09-30 | $1.09M 10-Q · filed 2022-11-14 | $1.18M 10-Q · filed 2022-11-14 | ||||||
| 2021-06-30 | $83.30K 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |